Histone Acetyltransferase (HAT) P300/CBP Inhibitors Induce Synthetic Lethality in PTEN-Deficient Colorectal Cancer Cells through Destabilizing AKT

Int J Biol Sci. 2020 Mar 25;16(11):1774-1784. doi: 10.7150/ijbs.42197. eCollection 2020.

Abstract

PTEN, a tumor suppressor, is found loss of function in many cancers, including colorectal cancer. To identify the synthetic lethal compounds working with PTEN deficiency, we performed a synthetic lethality drug screening with PTEN-isogenic colorectal cancer cells. From the screening, we found that PTEN-/- colorectal cancer cells were sensitive to anacardic acid, a p300/CBP histone acetyltransferase (HAT) inhibitor. Anacardic acid significantly reduced the viability of PTEN-/- cells not in PTEN+/+ cells via inducing apoptosis. Inhibition of HAT activity of p300/CBP by anacardic acid reduced the acetylation of histones at the promoter region and inhibited the transcription of Hsp70 family of proteins. The down-regulation of Hsp70 family proteins led to the reduction of AKT-Hsp70 complex formation, AKT destabilization and decreased the level of phosphorylated AKT at Ser473, all of which are vital for the survival of PTEN-/- colorectal cells. The synthetic lethality effect of anacardic acid was further validated in tumor xenograft mice models, where PTEN-/- colorectal tumors showed greater sensitivity to anacardic acid treatment than PTEN+/+ tumors. These data suggest that anacardic acid induced synthetic lethality by inhibiting HAT activity of p300/CBP, thereby reducing Hsp70 transcription and destabilizing AKT in PTEN deficient colorectal cancer cells.

Keywords: AKT; Anacardic acid; Histone acetyltransferases; Hsp70; PTEN; Synthetic lethality.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anacardic Acids / chemistry
  • Anacardic Acids / pharmacology
  • Anacardic Acids / therapeutic use*
  • Animals
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / pathology
  • Combinatorial Chemistry Techniques
  • Down-Regulation
  • Drug Design
  • Drug Discovery
  • Gene Deletion
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Male
  • Mice
  • Neoplasms, Experimental
  • PTEN Phosphohydrolase / deficiency*
  • PTEN Phosphohydrolase / metabolism
  • Prostatic Neoplasms / drug therapy
  • Proto-Oncogene Proteins c-akt*
  • Synthetic Lethal Mutations
  • Tumor Cells, Cultured
  • Xenograft Model Antitumor Assays
  • p300-CBP Transcription Factors / antagonists & inhibitors*
  • p300-CBP Transcription Factors / metabolism

Substances

  • Anacardic Acids
  • anacardic acid
  • p300-CBP Transcription Factors
  • Proto-Oncogene Proteins c-akt
  • PTEN Phosphohydrolase
  • PTEN protein, human